Lack of efficacy can be explained by well-defined tumor escape mechanisms [67]–[69], which are currently being addressed by combining DC vaccination with other approaches, such as CTLA4 [70] or CD25 blockade [52]. Here, CTLA4 is linked to neoplasm.